Drugs for obstructive airway diseases

Key figures

PRESCRIBERS
Main prescribers: General practitioners	72.52%
INSURED CONSUMERS
% of insured consumers	15.73%
Median age	48 years
Max/min ratio of the median age (by district)	1.26
Percentage of women	53.78%
Ratio Preferential scheme/General scheme	1.17
Coefficient of variation (2023)	17.87
Max/min ratio of % of insured consumers (by district)	1.87
CONSUMPTION
Annual consumption (DDD)	247,574,990
Consumption of DDD (per 100,000 insured persons)	2,148,994.25
% DDD issued outside the insurance (approximate)	3.15%
Average annual consumption per insured consumer (DDD)	136.63
% of insured consumers with > 3 times the average consumption	7,67%
Coefficient of variation 2013-2015	10.70
Coefficient of variation 2021-2023	13.58
Trend 2013-2023	-0.33%
Trend 2013-2021	-1.10%
Trend 2021-2023	2.81%
DIRECT EXPENDITURE (DDD)
Annual expenditure charged to the insurance	262,252,036 €
Average annual expenditure per insured person	22.76 €
Average patient share per insured consumer	11.83%
Max/min ratio of expenditure per insured person (by disctrict)	1.40
% “Low-cost” medication	43.52%
Trend 2013-2023	2.74%
Trend 2021-2023	8.74%

On this table, when a statistical test has been performed, the data showing a significant difference is displayed on a yellow background, otherwise on a grey background.

Data

ATC codes selected for analysis

CODES (ATC-5)	LABELS
R03AB	NON-SELECTIVE BETA-ADRENORECEPTOR AGONISTS
R03AC	SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
R03AK	ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03AL	ADRENERGICS IN COMBINATION WITH ANTICHOLINERGICS
R03BA	GLUCOCORTICOIDS
R03BB	ANTICHOLINERGICS
R03BC	ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS
R03CA	ALPHA- AND BETA-ADRENORECEPTOR AGONISTS
R03CC	SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
R03DA	XANTHINES
R03DC	LEUKOTRIENE RECEPTOR ANTAGONISTS
R03DX	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES